JP2024099041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024099041A5 JP2024099041A5 JP2024073463A JP2024073463A JP2024099041A5 JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5 JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024073463 A JP2024073463 A JP 2024073463A JP 2024099041 A5 JP2024099041 A5 JP 2024099041A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- atom
- acceptable salt
- compound according
- pharmacologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018167369 | 2018-09-06 | ||
| JP2018167369 | 2018-09-06 | ||
| PCT/JP2019/035198 WO2020050406A1 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2020541321A JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023050936A Division JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099041A JP2024099041A (ja) | 2024-07-24 |
| JP2024099041A5 true JP2024099041A5 (enExample) | 2025-01-14 |
Family
ID=69722459
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2024073463A Pending JP2024099041A (ja) | 2018-09-06 | 2024-04-30 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541321A Active JP7254818B2 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
| JP2023050936A Active JP7483975B2 (ja) | 2018-09-06 | 2023-03-28 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12370263B2 (enExample) |
| EP (2) | EP4524154A3 (enExample) |
| JP (3) | JP7254818B2 (enExample) |
| KR (4) | KR102810513B1 (enExample) |
| CN (3) | CN118846110A (enExample) |
| AU (2) | AU2019337051B2 (enExample) |
| BR (1) | BR112021003472A2 (enExample) |
| CA (1) | CA3251690A1 (enExample) |
| CO (1) | CO2021004032A2 (enExample) |
| DK (1) | DK3848054T3 (enExample) |
| ES (1) | ES3017008T3 (enExample) |
| FI (1) | FI3848054T3 (enExample) |
| HR (1) | HRP20250345T1 (enExample) |
| HU (1) | HUE071437T2 (enExample) |
| IL (2) | IL281247B2 (enExample) |
| LT (1) | LT3848054T (enExample) |
| MX (1) | MX2021002107A (enExample) |
| PH (1) | PH12021550442A1 (enExample) |
| PL (1) | PL3848054T3 (enExample) |
| PT (1) | PT3848054T (enExample) |
| RS (1) | RS66662B1 (enExample) |
| SG (1) | SG11202101526YA (enExample) |
| SI (1) | SI3848054T1 (enExample) |
| SM (1) | SMT202500141T1 (enExample) |
| TW (2) | TWI861820B (enExample) |
| WO (1) | WO2020050406A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202500141T1 (it) * | 2018-09-06 | 2025-05-12 | Daiichi Sankyo Co Ltd | Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici |
| EP4115909A4 (en) * | 2020-03-06 | 2024-10-30 | Daiichi Sankyo Company, Limited | ANTIBODY-DRUG CONJUGATE WITH NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE |
| EP4134098A4 (en) | 2020-04-10 | 2024-05-15 | ONO Pharmaceutical Co., Ltd. | Method of cancer therapy |
| TW202227479A (zh) * | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| CN116867795A (zh) * | 2021-02-01 | 2023-10-10 | 第一三共株式会社 | 抗体－免疫刺激剂偶联物的新型制造方法 |
| TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體－免疫賦活化劑共軛物之新穎製造方法 |
| IL305816A (en) | 2021-03-12 | 2023-11-01 | Daiichi Sankyo Co Ltd | Glycan and a method for preparing a medicine containing it |
| JP2024514683A (ja) * | 2021-04-23 | 2024-04-02 | ユニバーシティ オブ メリーランド， カレッジ パーク | 部位特異的抗体コンジュゲーションのためのＦｃグリカンリモデリングプラットフォーム法及びその適用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN115703845A (zh) * | 2021-08-05 | 2023-02-17 | 中国科学院上海药物研究所 | 寡糖连接子与侧链亲水性片段组合的糖链定点抗体-药物偶联物，其制法及用途 |
| EP4420682A1 (en) * | 2021-10-12 | 2024-08-28 | Chengdu Scimount Pharmatech Co., Ltd. | Highly-stable targeted linker-drug conjugate |
| EP4424717A4 (en) | 2021-10-29 | 2025-11-05 | Daiichi Sankyo Co Ltd | NEW OLIGOSACCHARIDE, INTERMEDIATE FOR THE MANUFACTURE OF A NEW OLIGOSACCHARIDE AND METHOD FOR MANUFACTURE THESE |
| EP4442828A4 (en) | 2021-11-30 | 2025-11-12 | Daiichi Sankyo Co Ltd | Masked antibodies cleavable by protease |
| US20250170255A1 (en) | 2022-02-09 | 2025-05-29 | Daiichi Sankyo Company, Limited | Environmentally-responsive masked antibody and use thereof |
| KR20240155298A (ko) | 2022-03-02 | 2024-10-28 | 다이이찌 산쿄 가부시키가이샤 | Fc 함유 분자의 제조 방법 |
| JP2025166269A (ja) * | 2022-07-29 | 2025-11-06 | 第一三共株式会社 | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 |
| WO2024048490A1 (ja) | 2022-08-29 | 2024-03-07 | 第一三共株式会社 | 変異Ｆｃ領域を含む抗体薬物コンジュゲート |
| JPWO2024053574A1 (enExample) | 2022-09-09 | 2024-03-14 | ||
| WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
| EP4626553A2 (en) | 2022-11-30 | 2025-10-08 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| WO2025164597A1 (ja) * | 2024-01-29 | 2025-08-07 | 第一三共株式会社 | 抗ｈｅｒ２抗体－薬物コンジュゲートと他剤との組み合わせ |
| WO2025183064A1 (ja) * | 2024-02-28 | 2025-09-04 | 第一三共株式会社 | 抗ｃｄｈ６抗体－薬物コンジュゲートと他剤との組み合わせ |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| CA2465314C (en) | 2001-11-01 | 2013-12-10 | The Uab Research Foundation | Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ATE535254T1 (de) | 2002-07-15 | 2011-12-15 | Genentech Inc | Behandlung von krebs mit dem anti-erbb2- antikörper rhumab 2c4 |
| DK1594542T3 (da) | 2003-02-20 | 2010-10-11 | Seattle Genetics Inc | Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer |
| CA2647632C (en) | 2006-03-27 | 2017-06-27 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| DK2199390T3 (en) | 2007-08-30 | 2017-04-03 | Daiichi Sankyo Co Ltd | ANTI-EphA2 ANTIBODY |
| WO2011027868A1 (ja) | 2009-09-03 | 2011-03-10 | 公益財団法人野口研究所 | １１糖シアリルオリゴ糖ペプチドの製造方法 |
| US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
| US9175326B2 (en) | 2011-03-03 | 2015-11-03 | University Of Maryland, Baltimore | Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae |
| CN104220603B (zh) | 2012-02-10 | 2017-06-06 | 马里兰大学，巴尔的摩 | 抗体及其Fc片段的化学酶法糖基化工程 |
| KR102237639B1 (ko) | 2012-10-11 | 2021-04-07 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트 |
| EA201590396A1 (ru) | 2012-12-13 | 2015-12-30 | Адуро Биотек, Инк. | Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения |
| MX365661B (es) | 2012-12-19 | 2019-06-10 | Univ Texas | Activacion farmaceutica de una senda de señalizacion de di-nucleotido ciclico de mamifero. |
| CA2908154C (en) | 2013-04-29 | 2023-11-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| JP6400082B2 (ja) | 2013-05-18 | 2018-10-03 | アデュロ バイオテック，インコーポレイテッド | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を抑制するための組成物および方法 |
| US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
| WO2015057063A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| US20160235861A1 (en) | 2013-10-14 | 2016-08-18 | SynAffix. B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| WO2015057066A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
| US9987373B2 (en) | 2013-10-14 | 2018-06-05 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
| US10092644B2 (en) | 2013-11-22 | 2018-10-09 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| ES2692226T3 (es) | 2014-06-04 | 2018-11-30 | Glaxosmithkline Intellectual Property Development Limited | Dinucleótidos cíclicos como moduladores de STING |
| DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
| EP4530348A3 (en) | 2014-12-15 | 2025-08-06 | Basf Se | Detergent composition comprising subtilase variants |
| US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
| HK1247089A1 (zh) | 2015-03-10 | 2018-09-21 | Aduro Biotech, Inc. | 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法 |
| WO2016161372A1 (en) | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| US11173213B2 (en) * | 2015-06-29 | 2021-11-16 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| KR102546854B1 (ko) | 2015-07-16 | 2023-06-22 | 다이이찌 산쿄 가부시키가이샤 | 신규 EndoS 변이 효소 |
| EP3334742B1 (en) | 2015-08-12 | 2019-05-08 | H. Hoffnabb-La Roche Ag | Bace1 inhibitors |
| GEP20207182B (en) | 2015-08-13 | 2020-11-25 | Merck Sharp & Dohme | Cyclic di-nucleotide compounds as sting agonists |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| UY36969A (es) | 2015-10-28 | 2017-05-31 | Novartis Ag | Composiciones y métodos para activar la señalización dependiente del estimulador del gen de interferon |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| MX363780B (es) | 2015-12-03 | 2019-04-03 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón. |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| WO2017123657A1 (en) | 2016-01-11 | 2017-07-20 | Gary Glick | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
| SMT202500412T1 (it) | 2016-01-11 | 2025-11-10 | Innate Tumor Immunity Inc | Dinucleotidi ciclici per il trattamento di condizioni associate all’attività di sting quali il cancro |
| CN114751950B (zh) | 2016-03-18 | 2025-04-18 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| US11486223B2 (en) | 2016-04-07 | 2022-11-01 | Chevron U.S.A. Inc. | Method for sealing a void in a well using smart gels |
| AU2017246802B2 (en) | 2016-04-07 | 2021-04-01 | Chevron U.S.A. Inc. | Smart gel sealants for well systems |
| JOP20170083B1 (ar) | 2016-04-07 | 2022-03-14 | Glaxosmithkline Ip Dev Ltd | أميدات هتيروسيكلية مفيدة كمعدلات بروتين |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| CN109462989A (zh) | 2016-07-01 | 2019-03-12 | 第三共株式会社 | Hanp-含fc分子缀合物 |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| EP3481402A4 (en) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE |
| US20190345191A1 (en) | 2016-08-31 | 2019-11-14 | Innate Tumor Immunity, Inc. | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| TN2020000158A1 (en) | 2016-10-04 | 2022-04-04 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| WO2018065360A1 (de) | 2016-10-07 | 2018-04-12 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
| CA3036941C (en) | 2016-10-07 | 2023-02-21 | Daiichi Sankyo Company, Limited | Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate |
| JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
| JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
| AU2017378783A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| TW202530271A (zh) | 2017-05-15 | 2025-08-01 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| JP6967739B2 (ja) | 2017-11-14 | 2021-11-17 | パナソニックＩｐマネジメント株式会社 | 給湯機 |
| SMT202500141T1 (it) | 2018-09-06 | 2025-05-12 | Daiichi Sankyo Co Ltd | Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici |
-
2019
- 2019-09-06 SM SM20250141T patent/SMT202500141T1/it unknown
- 2019-09-06 PT PT198574337T patent/PT3848054T/pt unknown
- 2019-09-06 CN CN202410810871.3A patent/CN118846110A/zh active Pending
- 2019-09-06 HR HRP20250345TT patent/HRP20250345T1/hr unknown
- 2019-09-06 PL PL19857433.7T patent/PL3848054T3/pl unknown
- 2019-09-06 EP EP25154566.1A patent/EP4524154A3/en active Pending
- 2019-09-06 AU AU2019337051A patent/AU2019337051B2/en active Active
- 2019-09-06 SI SI201930902T patent/SI3848054T1/sl unknown
- 2019-09-06 DK DK19857433.7T patent/DK3848054T3/da active
- 2019-09-06 CN CN201980058151.3A patent/CN112714649B/zh active Active
- 2019-09-06 MX MX2021002107A patent/MX2021002107A/es unknown
- 2019-09-06 KR KR1020237027378A patent/KR102810513B1/ko active Active
- 2019-09-06 HU HUE19857433A patent/HUE071437T2/hu unknown
- 2019-09-06 WO PCT/JP2019/035198 patent/WO2020050406A1/ja not_active Ceased
- 2019-09-06 LT LTEPPCT/JP2019/035198T patent/LT3848054T/lt unknown
- 2019-09-06 IL IL281247A patent/IL281247B2/en unknown
- 2019-09-06 ES ES19857433T patent/ES3017008T3/es active Active
- 2019-09-06 SG SG11202101526YA patent/SG11202101526YA/en unknown
- 2019-09-06 CN CN202410810879.XA patent/CN118878620A/zh active Pending
- 2019-09-06 TW TW112114344A patent/TWI861820B/zh active
- 2019-09-06 JP JP2020541321A patent/JP7254818B2/ja active Active
- 2019-09-06 FI FIEP19857433.7T patent/FI3848054T3/fi active
- 2019-09-06 TW TW108132368A patent/TWI825170B/zh active
- 2019-09-06 US US17/273,666 patent/US12370263B2/en active Active
- 2019-09-06 CA CA3251690A patent/CA3251690A1/en active Pending
- 2019-09-06 KR KR1020257016237A patent/KR20250078590A/ko active Pending
- 2019-09-06 RS RS20250327A patent/RS66662B1/sr unknown
- 2019-09-06 IL IL315138A patent/IL315138A/en unknown
- 2019-09-06 KR KR1020217009642A patent/KR102567590B1/ko active Active
- 2019-09-06 KR KR1020237005621A patent/KR102567591B1/ko active Active
- 2019-09-06 EP EP19857433.7A patent/EP3848054B1/en active Active
- 2019-09-06 BR BR112021003472-2A patent/BR112021003472A2/pt unknown
-
2021
- 2021-03-02 PH PH12021550442A patent/PH12021550442A1/en unknown
- 2021-03-30 CO CONC2021/0004032A patent/CO2021004032A2/es unknown
-
2023
- 2023-02-27 AU AU2023201159A patent/AU2023201159B2/en active Active
- 2023-03-28 JP JP2023050936A patent/JP7483975B2/ja active Active
-
2024
- 2024-04-22 US US18/642,667 patent/US20240293567A1/en active Pending
- 2024-04-30 JP JP2024073463A patent/JP2024099041A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024099041A5 (enExample) | ||
| CN110430901B (zh) | 制备葡糖苷酸药物-接头及其中间体的方法 | |
| US7968586B2 (en) | Cytotoxic compounds and conjugates | |
| US20060247295A1 (en) | Cytotoxic compounds and conjugates with cleavable substrates | |
| WO2017165851A1 (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| US20060004081A1 (en) | Cytotoxic compounds and conjugates | |
| CN103570792B (zh) | 蟾毒灵衍生物、其制备方法、药物组合物及用途 | |
| WO2018148650A1 (en) | Trigger-activatable sugar conjugates for cancer-selective labeling and targeting | |
| KR20080068084A (ko) | 씨씨-1065 유사체를 제조하기 위한 방법 및 화합물 | |
| JP2006511534A5 (enExample) | ||
| JPWO2020028608A5 (enExample) | ||
| PL195014B1 (pl) | Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie | |
| JPWO2019213445A5 (enExample) | ||
| US20130005696A1 (en) | Bufadienolide derivatives, preparing process thereof, composition comprising the same and the use thereof | |
| JP5612467B2 (ja) | Ｆｍｏｃをベースとした加水分解性リンカーの調製方法 | |
| CN111417408B (zh) | 药物接头化合物的制备方法 | |
| JP2002533418A (ja) | アントラキノン抗癌剤 | |
| JPWO2023020457A5 (enExample) | ||
| US20250161506A1 (en) | Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment | |
| JP4590198B2 (ja) | 葉酸誘導体の製造方法 | |
| KR20170041562A (ko) | 벤조셀레노펜계 화합물 및 이를 포함하는 항체-약물 결합체 | |
| KR102622992B1 (ko) | 이미다졸린 유도체 및 이의 중간체 제조방법 | |
| CN116715678B (zh) | 一种吲哚糖碳苷类大环化合物及其制备方法与应用 | |
| FI3441386T3 (fi) | Menetelmä yksöissuojattujen bifunktionaalisten aihiolääkkeiden syntetisoimiseksi ja niihin perustuvia vasta-aine-lääkekonjugaatteja sekä menetelmä vasta-aine-lääkekonjugaattien valmistamiseksi | |
| WO2024248944A1 (en) | Topoisomerase inhibitors, methods of making, and methods of use thereof |